|Year : 2019 | Volume
| Issue : 2 | Page : 71-79
QT interval – Its measurement and clinical significance
Sita Ram Mittal DM (Cardiology)
Department of Cardiology, Mittal Hospital and Research Centre, Ajmer, Rajasthan, India
|Date of Web Publication||3-Apr-2019|
Sita Ram Mittal
Xi/101, Brahmpuri, Ajmer - 305 001, Rajasthan
Source of Support: None, Conflict of Interest: None
QT interval extends from the beginning of QRS complex to the end of T wave. Thus, it includes the duration of ventricular depolarization (QRS) and repolarization (J point to end of T wave). It corresponds to the duration of cellular action potential. “long-” and “short”-QT intervals are considered as risk markers for cardiac arrhythmias and sudden death. In the last decade, there have been significant advances in our understanding about measurement and significance of QT interval. We have made an attempt to review the literature to find the limitations and queries surrounding the present status of measurement of QT interval and its significance as a risk marker for cardiac arrhythmias and sudden death.
Keywords: Arrhythmias, electrocardiography, repolarization heterogeneity, sudden cardiac death, torsades de pointes
|How to cite this article:|
Mittal SR. QT interval – Its measurement and clinical significance. J Clin Prev Cardiol 2019;8:71-9
| Introduction|| |
QT interval extends from the beginning of QRS complex to the end of T wave. It corresponds to the duration of action potential.
| (A) Measurement|| |
(a) Current understanding
At present, available electrocardiogram (ECG) machines can automatically measure QT interval and corrected QT (QTc) interval. Machines computing data from multiple leads give more accurate information than those which analyze only single lead. Automated measurement by ECG machines should, however, be confirmed by manual measurement, especially if there is difference between automated measurement and visual impression. Such problem is likely to occur when T wave is notched, biphasic, or relatively flat.,, QT interval is measured from the beginning of QRS to the end of T wave irrespective of whether the QRS complex begins with “Q” wave or “R” wave. It is measured from the lead in which it is longest (usually leads V2 or V3)., This is necessary because in some leads initial part of QRS and/or terminal part of T wave may be isoelectric resulting in false shortening of QT interval. Mean of at least three beats is taken in the same lead. Accurate measurement can be made only after a series of regular equal cycles during stable sinus rhythm.
At times, end of T wave and its junction with T-P segment is not sharp producing difficulty in defining exact end of T wave. In such situation, end of T wave is taken as the point where a tangent drawn from the steep portion of the downslope of T wave touches the isoelectric line.,
(i) Measurement of end of T wave is not clear
There is no consensus regarding measuring of QT interval when a “U” wave fuses with the end of T wave masking the exact point of end of T wave. Some authors feel that the point where a tangent extending from the downslope of T wave touches the baseline should be taken as the end of T wave. However, this might underestimate the QT interval. Al-Akehar and Siddique suggested that the “U” wave should be included in the QT measurement. However, this is likely to result in overestimation of QT interval. Further, there are no accepted reference values for the “normal” and prolonged QU interval. Some authors have suggested measuring QT interval in leads in which a prominent U wave is absent (usually lead aVR and aVL). However, this QT interval may not be the longest. Most of the authors feel that the point of notch between “T” and “U” wave can be taken as the end of T wave.,,, This is not the true end-point of the T wave, but it does for practical purposes.
If T wave is notched or bifid, end of the terminal wave can be taken to measure the QT interval. In tachycardia, end of T wave may fuse with the beginning ofPwave. In such a situation, junction of T andPwaves can be taken as the end of T wave for practical purposes. However, there is no evidence that this is the true QT interval.
Due to above-mentioned differences in opinion, there can be considerable interobserver variability in manual measurement of QT interval. Therefore, if the end of T wave is not clear, method used to determine the end of T wave should be mentioned in the report.
(ii) Measurement in the presence of broad QRS
There is currently no agreed consensus on how to measure the QT interval in patients with broad QRS, paced ventricular rhythm, or atrial fibrillation. Measurement of J-T interval has been suggested for detection of prolonged repolarization in ventricular conduction defect. However, its use has not been validated. Further, J-T interval has strong correlation with ventricular rate. Normal limits for rate adjusted J-T interval have not been established for ventricular conduction defect or for normal ventricular conduction. J-T interval, therefore, does not give correct information about QT interval in the presence of ventricular conduction defect. Bogossian et al. suggested that in the presence of left bundle branch block (LBBB), native QT interval (QT interval before development of LBBB) can be calculated as measured QT interval −50% of LBBB duration. However, it can cause overcorrection of QT interval. Further, this formula does not tell the correct QT interval in the presence of LBBB. This is especially important because factors that lead to the development of LBBB (e.g. myocardial ischemia) may also prolong QT. Finding native QT interval does not have much clinical significant once LBBB has developed. We should be able to determine QT interval after the development of LBBB. There is no literature on measurement of QT interval in patients of right bundle branch block, fascicular blocks, nonspecific intraventricular conduction defects, and paced rhythm.
| (B) Correction for Heart Rate|| |
With increasing heart rate, repolarization shortens so that myocardium is excitable when the next impulse comes. QT interval, therefore, shortens with increasing heart rate. Therefore, exact significance of QT interval can be judged only after correcting it for heart rate. QTc interval is called “QTc.”
(a) Formulae for correction
(i) Current understanding
Several formulae have been proposed for correction of QT interval.,
Bazett's formula is most commonly used. It is as follows:
R-R is the preceding R-R interval. QT is measured in milliseconds and RR is measured in seconds. It works best between heart rate of 60–100 beats/min. It may give erroneous results at both slower (overcorrection) and faster heart rates (undercorrection).
Linear Framingham method for correction of QT interval is as follows:
QTC = QT + 0.154 (1-RR)
It may give more uniform rate correction over wider range of heart rates.
Fridericia formula for QT interval correction is as follows:
QTc = QT/(R-R)0.33
This formula fails at high heart rates.
Another formula suggested for rate correction is as follows:
QTc = QT + 1.75 (HR-60).
HR is heart rate. Intervals are measured in milliseconds. It has been shown to be relatively insensitive to heart rate.
All formulae have some or other shortcoming. For a given ECG, there can be significant difference in the results of various formulae. Therefore, the formula used for correction should be mentioned in the report. Bazett's formula is easy to use and gives reasonably working information in most of the patients with normal heart rates. Most of the studies on QT interval have used this formula. It is most commonly used.
(b) Heart rate-QT interval nomogram
(i) Current understanding
One heart rate-QT interval nomogram has been described for stratification of risk of torsades de pointes in drug-induced QT prolongation. QT interval is measured manually and then plotted against the heart rate on the QT nomogram. Nomogram takes heart rate rather than R-R interval. Higher is the QT– heart rate pair above the nomogram, greater is the risk of drug-induced torsades de pointes.
- The nomogram does not correct the QT interval for heart rate. It only gives some impression about risk of torsades de pointes of a given QT interval and heart rate. It is important to remember that several other factors contribute to the risk of drug-induced torsades de pointes at a given QT interval. Further, there is substantial intersubject variability in the relation between heart rate and QT interval
- Nomogram has been validated only for evaluation of drug-induced QT prolongation. It has not been validated in other causes of QT prolongation. The relationship between QT interval, heart rate, and risk is uncertain at rapid heart rate. Therefore, an interrupted nomogram line has been used for heart rates above 104/min. Therefore, nomogram cannot be used reliably at fast heart rate.
Thus, no formula or nomogram provides an ideal rate correction for a given subject in a particular clinical setting. This is especially true when assessing the minor changes of QT interval induced by drugs.
(c) Correction in irregular rhythm
(i) Current understanding
It is not possible to measure correct QT interval in irregular rhythm, for example, in sinus arrhythmia, atrial fibrillation, or frequent ectopic beats. QT interval may be prolonged in ectopic and postectopic beat. Although it is not the correct QT, such phenomena may suggest increased risk of arrhythmias in patients with long QT.
Musat et al. correlated QT interval correction methods during atrial fibrillation and sinus rhythm. They observed that Fridericia method most closely approximates the QTc interval during atrial fibrillation to QTc during sinus rhythm. Patients were being treated with dofetilide. They studied the last ECG in atrial fibrillation to the first ECG in sinus rhythm. Therefore, their observation cannot be extrapolated to a routine case of atrial fibrillation.
| (C) Normal Value of Qtc|| |
(i) Current understanding
Previously, normal upper limit of QTc was considered as 460 ms for women and 450 ms for male. Subsequently, valves of 470 ms for male and 480 ms for female were suggested as limits of normality. Later, values of 440–450 ms in men and 440–470 ms in women were considered as borderline. Recent European guidelines for the management of patients with ventricular arrhythmias and prevention of sudden cardiac death have, however, suggested that QTc normally ranges between 360 ms and 480 ms.
QTc interval is affected by age, sex, sympathetic tone, posture, meals, heart rate, and diurnal pattern.,, Therefore, minor fluctuations should not be given undue importance and a rigid cut of value is not justified. A tip that helps identify normal QT interval on visual ECG examination is that it is less than half of the preceding R-R interval. QTc >500 ms predisposes to torsades de pointes.,,
| (D) Qt Dispersion|| |
(i) Current understanding
Onset of QRS and end of T wave do not occur simultaneously in every lead. QT interval, therefore, varies from lead to lead. This variation in QT interval is known as dispersion of QT interval (QTD). Initially, it was considered as an indicator of arrhythmogenicity.,
- Subsequent studies did not confirm initial impression of relation with arrhythmogenicities
- Reported normal values vary widely (10–71 ms)
- Main cause of QT dispersion is, in fact, the unreliable localization of the end of T wave
- Depending on QRS vector, initial part of QRS may be isoelectric in some leads. This results in incorporation of q wave in the P-R segment. It also contributes to QTD
- QT dispersion is sensitive to age, time of day, season of year, and even body position
- QTD per se does not represent underlying heterogeneity in repolarization and does not itself confer increased cardiovascular risk
- It has not been found to be a clinically useful parameter and is no longer used.
| (E) Significance of Variations in Qt Interval|| |
(1) Prolonged QT
Initially, prolonged QT interval per se was considered to be a very important risk factor for cardiac arrhythmias and sudden death. Over the past two decades, there has been significant advancement in our understanding of significance of prolonged QT interval. Following conclusions can be drawn from the literature.
(a) Congenital or familial prolongation of QT
(i) Current understanding
Congenital prolongation of QT interval is caused by mutation in ion channels (potassium, calcium, or sodium). More than 15 mutations have been identified. Hereditary long QT syndromes (Jervell Lange–Nielson syndrome, Romano–Ward syndrome, Andersen–Tawil syndrome, and Timothy syndrome) are associated with high risk of cardiac events. Other mutations in long QT susceptibility genes may or may not manifest QT prolongation on a resting 12-lead surface ECG, and are mostly without consequence.
- Triggers such as exertion, swimming, emotion, auditory stimuli, and postpartum period can rarely increase electrical instability of heart resulting in potentially life-threatening arrhythmias., In these cases, a normal QT interval does not exclude the risk
- Some gene suggestive electrocardiographic findings have been suggested. LQT1 is frequently associated with broad-based T wave. LQT2 is usually associated with low amplitude, notched, or biphasic T wave. Long isoelectric ST segment followed by a narrow-based T wave is common in LQT3. However, exceptions to these relative gene-specific T wave patterns exist. These T wave patterns can only raise suspicion of type of long QT syndrome from among the three common types in the absence of genetic testing (primarily due to cost issues). These T wave changes can give clue to propensity for syncopal attacks due to torsades de pointes in patients with long QT syndrome. Significance of these T wave patterns in general population is also not clear
- T wave alternans is defined as beat-to-beat change in amplitude or polarity of the T wave. It may be present at rest or may appear during emotional or physical stress or with drug-induced QT prolongation. It has been observed as a precursor to torsades de pointes in some cases. Independent significance of this finding in persons without other risk factors is not clear
- It has been suggested that in patients with strong clinical suspicion, abnormal QT interval may be unmasked by sudden standing, or during recovery from exercise stress test., However, there is no documentation that these findings correlate with risk of future cardiovascular events. Intravenous pharmacologic provocation testing (e.g. with epinephrine) can unmask inappropriate prolongation of the QTc interval. However, there is risk of induction of arrhythmias. It is also not clear if epinephrine-induced QT prolongation correlates with risk of arrhythmias in day-to-day life. As for today, the risk in such mutations with normal QTc interval in resting ECG can be evaluated confidently only be genetic study and not by the QT interval alone.,, However, genetic testing is limited by cost and is recommended only when there is strong clinical index of suspicion
- Many patients with unexplained congenital prolongation of QT interval never experience torsades de pointes. Reason is not clear. At present, there is no method to find which patients of congenitally prolonged QT interval are immune to life-threatening arrhythmias.
(b) Acquired prolongation of QT
Several acquired conditions are known to cause QT prolongation. Risk of serious arrhythmias is, however, variable.
(i) Heart failure, myocardial diseases, or coronary artery disease
| Controversy|| |
Risk of serious cardiovascular events in patients with cardiac disease depends on severity of underlying disease, magnitude of left ventricular dysfunction, electrolyte imbalance, presence of high degree or complete atrioventricular block, presence of bradycardia or pauses, frequent ventricular premature beats with compensatory pause, sustained ventricular tachycardia, and instability of repolarization and genetic susceptibility, rather than on QT interval prolongation alone. It is, therefore, not clear as to which patients with cardiac disease and prolonged QT interval will benefit from prophylaxis against life-threatening arrhythmias.
(ii) Electrolyte imbalance
Hypokalemia, hypomagnesemia, and hypocalcemia prolong QT interval.
| Controversy|| |
The risk correlates with magnitude of electrolyte imbalance, disturbance of other electrolytes, and concomitant cardiac status in addition to magnitude of QT interval prolongation.
(iii) Drug-induced QT prolongation
There is a long list of drugs that prolong QT interval. Common drugs include quinidine, piscarnomed, disopyramide, flecainide, sotalol, ibutilide, and cisapride. However, several other factors control occurrence of fatal arrhythmias.
In patients with drug-induced prolongation of QT interval, conclusions about the risk of torsades de pointes based solely on prolongation of QTc interval may turn out to be highly flawed. Risk is dependent on several factors as follows:
- Magnitude of QT prolongation
Patients who develop drug-induced torsades de pointes usually have QTc interval >500 ms, or there is more than 60–70 ms increase from baseline value. However, only a small subset of these patients develop torsades de pointes. Other factors contribute to the risk of torsades de pointes.
- Drug responsible for QT prolongation
List of drugs that can prolong QT interval is extensive. However, there is no documentation of torsades de pointes in most of the case reports. Some drugs rarely produce arrhythmias although they prolong QT interval, for example, amiodarone, dronedarone, ranolazine, lithium, terfenadine, astemizole, antibiotics, and antipsychotics.,, For some drugs as dofetilide, the risk of torsades de pointes is much higher.
- Dose, route, and rate of administration, drug metabolism, and excretion
Risk of sotalol-induced torsades de pointes is dose dependent. Risk of torsades de pointes with haloperidol is usual after intravenous injection.
- Concomitant use of other drugs prolonging QT
- Concomitant electrolyte imbalance, for example, hypokalemia, hypocalcemia, and hypomagnesemia,
- Underlying cardiac status, for example, heart failure, myocardial infarction, and active ischemia
- Genetic predisposition: Genetically determined reduced repolarization reserve or rate of drugs metabolism or excretion
- Subclinical mutations in congenital LQTS genes,,
- Renal and/or hepatic failure in patients being treated with drugs requiring renal elimination (e.g. sotalol) or hepatic metabolism (e.g. methadone).
In the absence of other factors, drug-induced QT prolongation alone rarely produces torsades de pointes and subsequent sudden death.
(iv) QT prolongation associated with intracerebral or subarachnoid hemorrhage and myxedema
QT prolongation in these conditions is usually not associated with increased risk of cardiac arrhythmias. Reason is not clear.
(2) Short QT interval
Short QT interval is considered as a risk factor for cardiac arrhythmias and sudden death. Normal lower limit is suggested as 390 ms.
Some authorities feel that QT interval <320 ms should be considered as “short.” It is considered realistic to prevent overdiagnosis and excessive investigations., However, the definition of a lower limit of QTc in short QT interval syndrome and its association with serious cardiac arrhythmias is less clear. QT interval <300 ms may not be associated with serious cardiac arrhythmias. It is possible that very short QTc (200–260 ms) may be associated with an increased cardiac risk. Markers other than QTc interval are needed to identify patients at risk.
(a) Congenital or familial short QT syndrome
It is due to mutation in some specific ion channels. Several specific genotypes have been identified. There is no structural heart disease. It has been observed that congenital short QT interval may be associated with increased risk of paroxysmal atrial fibrillation, syncope, or cardiac arrest. Episodes occur most often during periods of rest or sleep.
Some ECG findings have been suggested to be associated with congenital short QT syndrome. These include no or short ST segment and tall peaked T waves. Recent studies have, however, shown that there are no diagnostic electrocardiographic findings and risk is related to genetic mutation.,
(b) In general population
Short QT interval is rare and is not associated with increased cardiac risk.,,
(c) Early repolarization
It may be associated with short QT interval. Some patients with early repolarization syndrome (J wave syndromes) may be associated with increased risk of arrhythmias. However, increased risk is not related to shortening of QT interval.,
(d) Hypercalcemia, hypermagnesemia, and acidosis
These can shorten QT interval. Risk is related to magnitude of abnormality and severity of underlying disease rather than to shortening of QT interval.
Magnitude of shortening of QT interval in digitalis overdose has no relation to digitalis-induced arrhythmias which depend on concomitant electrolyte imbalance and underlying cardiac status.
(f) Other drugs
Clinical significance of QT shortening induced by other drugs is still under evaluation.
| (F) Subanalysis of Qt Interval|| |
Failure of QTc to reliably predict the risk of arrhythmias has resulted in evaluation of other electrocardiographic parameters to evaluate repolarization heterogeneity. Following parameters have been evaluated.
(1) J point to peak of T wave
(a) Current understanding
Normally, it is around 200 ms. In the presence of prolonged QT interval, it can exceed 300 ms. In setting of short QT interval, it can be as short as 100 ms. It is less sensitive to changes in posture and respiration-related changes in T wave morphology. It is affected by heart rate.
It has not been evaluated in detail in normal population and patients at high risk of cardiac arrhythmias. It is not clear if this parameter alone has any independent significance over other electrocardiographic parameters.
(2) Interval from peak of T wave to its end
(a) Current understanding
Most typically lead V5 is used for this measurement. Difficulties can arise in measurement particularly with low T wave amplitude or when T waves are notched or biphasic. It is less sensitive to changes in posture and respiration-related changes in T wave morphology. Control subjects have been shown to have a value of <90 ms., Some authors feel that this interval provides some measure of repolarization heterogeneity independently associated with sudden cardiac death.,, It has been suggested that the peak of T wave to its end (Tp-Te) interval may serve as an index of total dispersion of repolarization (transmural, apicobasal, and global). This interval has been used in predicting arrhythmias and sudden cardiac death in some cardiac channelopathies., Tp-Te >100 ms has been shown to predict malignant ventricular arrhythmias within 24 h of ST-segment elevation myocardial infarction.
- Genesis of arrhythmias and sudden death in the setting of acute coronary syndrome is also dependent on several other factors, for example, electrolyte imbalance, extent of infarction, left and right ventricular functions, extent of underlying coronary artery disease, and persistence of ischemia. Further, all patients with prolonged Tp-Te interval do not develop malignant arrhythmias. Therefore, it is difficult to determine additional independent prognostic significance of this interval in patients with acute coronary syndrome
- This interval has also been found to be prolonged in conditions such as coronary ectasia, nondipper blood pressure pattern in patients with metabolic syndrome, and patients with coronary slow flow. These conditions are not known to be associated with high risk of malignant arrhythmias and sudden death
- Arrhythmogenic risk of this parameter has not been evaluated in context of various drug, other conditions predisposing to arrhythmias, and patients without cardiovascular disease or risk factors.
Large randomized controlled trials with long-term follow-up are needed to find if this parameter alone has any independent clinical significance.
(3) Interval from peak of T wave to its end/QT ratio
(a) Current understanding
Normal range of this ratio is very wide (0.15–0.25). It remains relatively constant between the heart rate from 60 to 100 beats/min. Higher ratio (>0.30) has been linked to increased risk of arrhythmias in patients with long QT syndrome, Brugada syndrome, short QT syndrome, and acute myocardial infarction.,,,
- This interval has also been found to be prolonged in conditions such as coronary ectasia, nondipper blood pressure pattern in patients with metabolic syndrome, and patients with coronary slow flow. These conditions are not known to be associated with risk of malignant arrhythmias and sudden death.
- Arrhythmogenic risk of this parameter has not been evaluated in context of various drug, other conditions predisposing to malignant arrhythmias, and patients without cardiovascular disease or risk factors.
Large randomized controlled trials with long-term follow-up in “normal” population and in patients with other conditions known to prolong QT interval or associated with risk of malignant arrhythmias and sudden death are needed to find actual independent significance of this parameter.
(4) Status of various components of QT interval
(a) Current understanding
Different etiological factors affect different components of QT interval. Flecainide causes broadening of QRS. Tricyclic antidepressants also produce QRS widening without lengthening of J-T interval. Long QT3 syndrome is associated with long ST segment and late-onset T wave. Sotalol produces broad T wave with increased Tp-Te interval. ST elevation myocardial infarction also prolongs Tp-Te interval., In hypokalemia, it is the Q-U interval that is prolonged.
There is no literature regarding following issues:
- Duration of different components of QT interval in normal population
- Effect of age, gender, ethnic group, posture, and diurnal variation on
- various components of QT interval
- Effect of heart rate on various components of QT interval and method to correct them for given heart rate
- Abnormality of which channel affects which part of the QT interval?
- What is the clinical significance of prolongation of different components in normal population and in patients known to have high risk of arrhythmias and sudden death?
- Correlation of arrhythmogenic risk of various drugs and other factors to various parts of QT interval
- Will the management differ depending on prolongation of different components of QT interval?
Well-designed prospective studies with long-term follow-up are needed to answer these queries.
Controversies regarding QT interval are summarized in [Table 1].
| (H) Conclusion|| |
- Manual measurement of QT interval is associated with interindividual variability. Automated measurement and heart rate correction by ECG machine can give working information unless the ECG is abnormal. There is no consensus regarding measurement of QT interval if T wave is bifid or fuses with U orPwave, QRS is broad or rhythm is irregular
- There can be significant difference in the results of various formulae recommended for correction of QT interval for heart rate. Therefore, the formula used for rate correction should be mentioned in the report for proper follow-up of patient. Bazzett's formula is easy to use and gives reasonably working information in most of the patients
- Normal QTc interval has a wide range – 360–480 ms. QTc is also affected by sympathetic tone, posture, meals, and diurnal pattern. Therefore, undue significance should not be given to minor changes
- QT dispersion alone does not correlate with risk of arrhythmias
- Hereditary long QT syndromes are associated with increased risk of arrhythmias and sudden death. Other genetic mutations are mostly without consequences. In acquired prolonged QT interval, risk depends more on genetic predisposition, underlying cardiac status, and electrolyte or metabolic disturbances. All drugs prolonging QTc interval do not carry similar risk
- Hereditary short QT syndromes carry some risk of paroxysmal atrial fibrillation, syncope, or cardiac arrest. Most of the other cases do not have any risk
- Independent significance of various parts of QT interval is not clear.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Mirvis DM, Goldberger AL. Electrocardiography. In: Mann DL, Zipes DP, Libby P, Bonow RO, editors. Braunwald's Heart Disease. Philadelphia: Saunders; 2015. p. 114-52.
Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, et al.
AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, T and U waves, and the QT interval: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009;53:982-91.
Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol 2016;81:420-7.
Isbister GK. Risk assessment of drug-induced QT prolongation. Aust Prescr 2015;38:20-4.
Talebi S, Azhir A, Zuber S, Soman S, Visco F, Totouom-Tangho H, et al.
Underestimated and unreported prolonged QTc by automated ECG analysis in patients on methadone: Can we rely on computer reading? Acta Cardiol 2015;70:211-6.
Wagner GS, Lim TH. Cardiac electrical activity. In: Wagner GS, editor. Marriott's Practical Electrocardiography. Philadelphia: Wolters Kluwer; 2008. p. 1-20.
Sadanaga T, Sadanaga F, Yao H, Fujishima M. An evaluation of ECG leads used to assess QT prolongation. Cardiology 2006;105:149-54.
Postema PG, Wilde AA. The measurement of the QT interval. Curr Cardiol Rev 2014;10:287-94.
Wagner GS, Lim TH. Interpretation of normal electrocardiogram. In: Wagner GS, editor. Marriott's Practical Electrocardiography. Philadelphia: Wolters Kluwer; 2008. p. 43-70.
De Luna AB, Goldwasser D, Fiol M, Bayes Genis A. Surface electrocardiography. In: Fuster V, Walsh RA, Harrington RA, editors. Hurst's The Heart. New York: Mc Graw Hill; 2011. p. 307-70.
Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952;6:378-88.
Gomez AT, Prutkin JM, Rao AL. Evaluation and management of athletes with long QT syndrome. Sports Health 2016;8:527-35.
Schamroth L. Basic principles. In: Schamroth C, editor. An introduction to Electrocardiography. Delhi: Wiley India; 1982. p. 5-33.
Goldenberg I, Moss AJ, Zareba W. QT interval: How to measure it and what is “normal”. J Cardiovasc Electrophysiol 2006;17:333-6.
Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, et al.
Inaccurate electrocardiographic interpretation of long QT: The majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005;2:569-74.
QT interval and drug therapy (Clinical review from drug and therapeutics bulletin). BMJ 2016;354:i4331.
Rautaharju PM, Zhang ZM, Prineas R, Heiss G. Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol 2004;93:1017-21.
Bogossian H, Frommeyer G, Ninios I, Pechlivanidou E, Hasan F, Nguyen QS, et al.
A new experimentally validated formula to calculate the QT interval in the presence of left bundle branch block holds true in the clinical setting. Ann Noninvasive Electrocardiol 2017;22: doi:10.1111/anec.12393.
Wang B, Zhang L, Xia Y. Cutting off half of QRS duration can cause overcorrection of QT interval in left bundle branch block. Ann Noninvasive Electrocardiol 2017;22.
Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: The effect of heart rate on the QTc of normal ECGs. J Electrocardiol 2004;37 Suppl: 81-90.
Bazett HC. An analysis of the time relations of electrocardiogram. Heart 1920;7:353-70.
Fridericia LS. The systole duration in the electrocardiogram in normal people and in people with heart disease. Acta Med Scand 1920;53:469-86.
Rautaharju PM. QT and dispersion of ventricular repolarization: The greatest fallacy in electrocardiography in the 1990s. Circulation 1999;99:2477-8.
Chan A, Isbister GK, Kirkpatrick CM, Dufful SB. Drug-induced QT prolongation and torsades de pointes: Evaluation of a QT nomogram. QJM 2007;100:609-15.
Batchvarov VN, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P, et al.
QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002;282:H2356-63.
Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: A comprehensive review. ScientificWorldJournal 2012;2012:212178.
Musat DL, Adhaduk M, Preminger MW, Arshad A, Sichrovsky T, Steinberg JS, et al.
Correlation of QT interval correction methods during atrial fibrillation and sinus rhythm. Am J Cardiol 2013;112:1379-83.
Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al.
Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010;55:934-47.
Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al
. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-867.
Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J Physiol 2016;599:2459-68.
Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991;67:774-6.
Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: How long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996;27:76-83.
Day CP, McComb JM, Campbell RW. QT dispersion: An indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990;63:342-4.
Glancy JM, Garratt CJ, Woods KL, de Bono DP. QT dispersion and mortality after myocardial infarction. Lancet 1995;345:945-8.
Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000;36:1749-66.
Prenner SB, Shah SJ, Goldberger JJ, Sauer AJ. Repolarization heterogeneity: Beyond the QT interval. J Am Heart Assoc 2016;5. pii: e003607.
Molnar J, Somberg JC. The dynamics of QT dispersion. Cardiology 2009;113:169-71.
Miller JM, Zipes DP. Diagnosis of cardiac arrhythmias. In: Mann DL, Zipes DP. Libby P, Bonow RO, editors. Braunwald's Heart Disease. Philadelphia: Saunders; 2015. p. 662-76.
Tse G, Chan YW, Keung W, Yan BP. Electrophysiological mechanisms of long and short QT syndromes. Int J Cardiol Heart Vasc 2017;14:8-13.
Tester DJ, Ackerman MJ. Genetics of cardiac arrhythmias. In: Mann DL, Zipes DP, Libby P, Bonow RO, editors. Braunwald's Heart Disease. Philadelphia: Saunders; 2015. p. 617-23.
Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J Physiol 2016;594:2459-68.
Goldenberg I, Horr S, Moss AJ, Lopes CM, Barsheshet A, McNitt S, et al.
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011;57:51-9.
Zhang L, Timothy KW, Vincent GM, Lehmann MH, Fox J, Giuli LC, et al.
Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000;102:2849-55.
Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al.
Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm 2013;10:e85-108.
Grabowski M, Karpinski G, Filipiak KJ, Opolski G. Images in cardiovascular medicine. Drug-induced long-QT syndrome with macroscopic T-wave alternans. Circulation 2004;110:e459-60.
Viskin S, Postema PG, Bhuiyan ZA, Rosso R, Kalman JM, Vohra JK, et al.
The response of the QT interval to the brief tachycardia provoked by standing: A bedside test for diagnosing long QT syndrome. J Am Coll Cardiol 2010;55:1955-61.
Adler A, van der Werf C, Postema PG, Rosso R, Bhuiyan ZA, Kalman JM, et al.
The phenomenon of “QT stunning”: The abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm 2012;9:901-8.
Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation 2011;124:2181-4.
Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, et al.
Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation 2011;124:2187-94.
Couderc JP, Lopes CM. Short and long QT syndromes: Does QT length really matter? J Electrocardiol 2010;43:396-9.
Miller JN, Zipes DP. Therapy for cardiac arrhythmias. In: Mann DL, Zipes DP, Libby P, Bonow RO, editors. Braunwald's Heart Disease. Philadelphia: Saunders; 2015. p. 685-720.
Hasanien AA, Drew BJ, Howie-Esquivel J. Prevalence and prognostic significance of long QT interval in patients with acute coronary syndrome: Review of the literature. J Cardiovasc Nurs 2014;29:271-9.
Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-72.
Schwartz PJ, Woosley RL. Predicting the unpredictable: Drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol 2016;67:1639-50.
Woosley RL, Romero KA, Crediblemeds. Org QT Drugs List, 2016 AZCERT, Inc., 2016. Available from: https://www.crediblemeds.org
. [Last accessed on 2018 Jun 13].
Abraham JM, Saliba WI, Vekstein C, Lawrence D, Bhargava M, Bassiouny M, et al.
Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 2015;8:772-6.
Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990;65:74A-81A.
Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: How should institutions respond? J Hosp Med 2010;5:E8-16.
Itoh H, Crotti L, Aiba T, Spazzolini C, Denjoy I, Fressart V, et al.
The genetics underlying acquired long QT syndrome: Impact for genetic screening. Eur Heart J 2016;37:1456-64.
Niemeijer MN, van den Berg ME, Eijgelsheim M, Rijnbeek PR, Stricker BH. Pharmacogenetics of drug-induced QT interval prolongation: An update. Drug Saf 2015;38:855-67.
Ramirez AH, Shaffer CM, Delaney JT, Sexton DP, Levy SE, Rieder MJ, et al.
Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J 2013;13:325-9.
Weeke P, Mosley JD, Hanna D, Delaney JT, Shaffer C, Wells QS, et al.
Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol 2014;63:1430-7.
Wagner GS, Wang TY. Miscellaneous conditions. In: Wagner GS, editor. Marriott's Practical Electrocardiography. Philadelphia: Wolters Kluwer; 2008. p. 209-37.
Dhutia H, Malhotra A, Parpia S, Gabus V, Finocchiaro G, Mellor G, et al.
The prevalence and significance of a short QT interval in 18,825 low-risk individuals including athletes. Br J Sports Med 2016;50:124-9.
Funada A, Hayashi K, Ino H, Fujino N, Uchiyama K, Sakata K, et al.
Assessment of QT intervals and prevalence of short QT syndrome in Japan. Clin Cardiol 2008;31:270-4.
Pérez Riera AR, Paixão-Almeida A, Barbosa-Barros R, Yanowitz FG, Baranchuk A, Dubner S, et al.
Congenital short QT syndrome: Landmarks of the newest arrhythmogenic cardiac channelopathy. Cardiol J 2013;20:464-71.
Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, et al.
Short QT syndrome: A familial cause of sudden death. Circulation 2003;108:965-70.
Brugada R, Hong K, Cordeiro JM, Dumaine R. Short QT syndrome. CMAJ 2005;173:1349-54.
Reinig MG, Engel TR. The shortage of short QT intervals. Chest 2007;132:246-9.
Watanabe H, Makiyama T, Koyama T, Kannankeril PJ, Seto S, Okamura K, et al.
High prevalence of early repolarization in short QT syndrome. Heart Rhythm 2010;7:647-52.
Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm 2010;7:549-58.
Tikkanen JT, Anttonen O, Junttila MJ, Aro AL, Kerola T, Rissanen HA, et al.
Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med 2009;361:2529-37.
Shah RR. Drug-induced QT interval shortening: Potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol 2010;159:58-69.
Hondeghem LM. QTc prolongation as a surrogate for drug-induced arrhythmias: Fact or fallacy? Acta Cardiol 2011;66:685-9.
Brockway R, Brockway M, Brockway B, Hamlin R. Comparison of one- and three-lead ECG to measure cardiac intervals and differentiate drug-induced multi-channel block. J Pharmacol Toxicol Methods 2018;93:80-9.
Yamaguchi M, Shimizu M, Ino H, Terai H, Uchiyama K, Oe K, et al.
T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: A new index for arrhythmogenicity. Clin Sci (Lond) 2003;105:671-6.
Karaagac K, Yontar OC, Tenekecioglu E, Vatansever F, Ozluk OA, Tutuncu A, et al.
Evaluation of Tp-Te interval and Tp-Te/QTc ratio in patients with coronary artery ectasia. Int J Clin Exp Med 2014;7:2865-70.
Karaagac K, Tenekecioglu E, Yontar OC, Kuzeytemiz M, Vatansever F, Tutuncu A, et al.
Effect of non-dipper and dipper blood pressure patterns on Tp-Te interval and tp-te/QT ratio in patients with metabolic syndrome. Int J Clin Exp Med 2014;7:1397-403.
Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Hattenhauer J, Mariani R, et al.
Prolonged tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circ Arrhythm Electrophysiol 2011;4:441-7.
Kors JA, Ritsema van Eck HJ, van Herpen G. The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol 2008;41:575-80.
Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, Dorantes Sánchez M, Dorticós Balea F, Zayas Molina R, et al.
Tpeak-tend and tpeak-tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006;47:1828-34.
Kanters JK, Haarmark C, Vedel-Larsen E, Andersen MP, Graff C, Struijk JJ, et al.
T (peak) T (end) interval in long QT syndrome. J Electrocardiol 2008;41:603-8.
Shenthar J, Deora S, Rai M, Nanjappa Manjunath C. Prolonged tpeak-end and tpeak-end/QT ratio as predictors of malignant ventricular arrhythmias in the acute phase of ST-segment elevation myocardial infarction: A prospective case-control study. Heart Rhythm 2015;12:484-9.
Tenekecioglu E, Karaagac K, Yontar OC, Agca FV, Ozluk OA, Tutuncu A, et al.
Evaluation of Tp-Te interval and tp-te/QT ratio in patients with coronary slow flow tp-te/QT ratio and coronary slow flow. Eurasian J Med 2015;47:104-8.
Ravi Kiran G, Ramesh K, Chandrashekar V. Association between QTD, Tp-e/QT ratio and in hospital prognosis in thrombolysed acute ST-elevation myocardial elevation (STEMI) patients. J Assoc Physicians India 2017;65:34-9.
Gupta P, Patel C, Patel H, Narayanaswamy S, Malhotra B, Green JT, et al.
T (p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008;41:567-74.
Mugnai G, Benfari G, Fede A, Rossi A, Chierchia GB, Vassanelli F, et al.
Tpeak-to-tend/QT is an independent predictor of early ventricular arrhythmias and arrhythmic death in anterior ST elevation myocardial infarction patients. Eur Heart J Acute Cardiovasc Care 2016;5:473-80.
|This article has been cited by|
||Proposal of a pseudo-electrocardiogram model incorporating heart rate variability and QT-interval variability, and its application
| ||Tomohiro Ueyama, Ayaka Yoshino, Harunobu Nakamura, Yoshimitsu Okita |
| ||IEEJ Transactions on Electrical and Electronic Engineering. 2022; |
|[Pubmed] | [DOI]|
||Long QT Syndrome: Clinical and Genetic Diagnostic Complications
| || ?.?. ??????????, ?.?. ????????, ?.?. ??????????, ?.?. ???????, ?.?. ?????????, ?.?. ??????????, ?.?. ????????? |
| ||??????????? ? ????????. 2021; (5): 747 |
|[Pubmed] | [DOI]|
||Stability analysis on the effects of heart rate variability and premature activation of atrial ECG dynamics using ARMAX model
| ||Jyothsana Arumughan,Arya Bhardwaj,J. Sivaraman |
| ||Physical and Engineering Sciences in Medicine. 2020; |
|[Pubmed] | [DOI]|